Loading...
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial
Зохиогч
Batmunkh, Tsetsegsaikhan
Neal, Eleanor F G
Amraa, Otgonjargal
Mazarakis, Nadia
Altangerel, Bolor
Avaa, Naranbaatar
Batbayar, Lkhagvagaram
Batsukh, Khishigjargal
Bright, Kathryn
Burentogtokh, Tsogjargal
Do, Lien Anh Ha
Hart, John D
Jamiyandorj, Otgonbold
Javkhlantugs, Khulan
Jigjidsuren, Sarantsetseg
Justice, Frances
Li, Shuo
Mashbaatar, Khaliunaa
Moore, Kerryn A
Namjil, Narantuya
Nguyen, Cattram Duong
Ochirbat, Batbayar
Surenjav, Unursaikhan
Thomson, Helen
Licciardi, Paul V
von Mollendorf, Claire
Mulholland, Kim
Он
2025 оны арван нэгдүгээр сар
Төрөл
journal article
Хэвлэгч
Elsevier BV
Journal
Vaccine
Volume
66
Start Page
127840
ISSN
1873-2518
Хураангуй
BACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia.
METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented.
CLINICALTRIALS: gov Identifier: NCT05265065.
RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported.
CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.
